TNF-α mediates the stimulation of sclerostin expression in an estrogen-deficient condition

Biochemical and Biophysical Research Communications

Volumn 424, Issue 1, 2012, Pages 170-175

  Kim, Beom Jun ^a   Bae, Sung Jin ^a   Lee, Sun Young ^b   Lee, Young Sun ^b   Baek, Ji Eun ^b   Park, Sook Young ^b   Lee, Seung Hun ^a   Koh, Jung Min ^a   Kim, Ghi Su ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Asan Institute for Life Sciences   (South Korea)

Author keywords

Estrogen deficiency; Sclerostin; T cells; TNF

Indexed keywords

ESTRADIOL; ESTROGEN; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 6; LUCIFERASE; MYOCYTE ENHANCER FACTOR 2; PHOSPHATE BUFFERED SALINE; SCLEROSTIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ESTROGEN DEFICIENCY; FEMALE; FEMUR; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; OSTEOSARCOMA CELL; OVARIECTOMY; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REPORTER GENE; SHAM PROCEDURE; T LYMPHOCYTE; TRANSCRIPTION INITIATION; WESTERN BLOTTING;

ANIMALS; BONE AND BONES; BONE RESORPTION; CELL LINE, TUMOR; ESTROGENS; FEMALE; GLYCOPROTEINS; INTERLEUKIN-1; INTERLEUKIN-2; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MYOGENIC REGULATORY FACTORS; OSTEOGENESIS; OVARIECTOMY; RATS; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

MUS; MUS MUSCULUS; RATTUS;

EID: 84864077052     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.06.100     Document Type: Article

References (30)

1. Raisz L.G. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J. Clin. Invest. 2005, 115:3318-3325.
2. Bord S., Beavan S., Ireland D., Horner A., Compston J.E. Mechanisms by which high-dose estrogen therapy produces anabolic skeletal effects in postmenopausal women: role of locally produced growth factors. Bone 2001, 29:216-222.
3. Feng X., McDonald J.M. Disorders of bone remodeling. Annu. Rev. Pathol. 2011, 6:121-145.
4. Weitzmann M.N., Pacifici R. The role of T lymphocytes in bone metabolism. Immunol. Rev. 2005, 208:154-168.
5. Weitzmann M.N., Pacifici R. Estrogen deficiency and bone loss: an inflammatory tale. J. Clin. Invest. 2006, 116:1186-1194.
6. Kong Y.Y., Feige U., Sarosi I., Bolon B., Tafuri A., Morony S., Capparelli C., Li J., Elliott R., McCabe S., Wong T., Campagnuolo G., Moran E., Bogoch E.R., Van G., Nguyen L.T., Ohashi P.S., Lacey D.L., Fish E., Boyle W.J., Penninger J.M. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999, 402:304-309.
7. Manolagas S.C. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr. Rev. 2000, 21:115-137.
8. Gowen M., Mundy G.R. Actions of recombinant interleukin 1, interleukin 2, and interferon-gamma on bone resorption in vitro. J. Immunol. 1986, 136:2478-2482.
9. Li X., Zhang Y., Kang H., Liu W., Liu P., Zhang J., Harris S.E., Wu D. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J. Biol. Chem. 2005, 280:19883-19887.
10. Semenov M., Tamai K., He X. SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J. Biol. Chem. 2005, 280:26770-26775.
11. Li X., Ominsky M.S., Niu Q.T., Sun N., Daugherty B., D'Agostin D., Kurahara C., Gao Y., Cao J., Gong J., Asuncion F., Barrero M., Warmington K., Dwyer D., Stolina M., Morony S., Sarosi I., Kostenuik P.J., Lacey D.L., Simonet W.S., Ke H.Z., Paszty C. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J. Bone Miner. Res. 2008, 23:860-869.
12. Winkler D.G., Sutherland M.K., Geoghegan J.C., Yu C., Hayes T., Skonier J.E., Shpektor D., Jonas M., Kovacevich B.R., Staehling-Hampton K., Appleby M., Brunkow M.E., Latham J.A. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J. 2003, 22:6267-6276.
13. Loots G.G., Kneissel M., Keller H., Baptist M., Chang J., Collette N.M., Ovcharenko D., Plajzer-Frick I., Rubin E.M. Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. Genome Res. 2005, 15:928-935.
14. Balemans W., Ebeling M., Patel N., Van Hul E., Olson P., Dioszegi M., Lacza C., Wuyts W., Van Den Ende J., Willems P., Paes-Alves A.F., Hill S., Bueno M., Ramos F.J., Tacconi P., Dikkers F.G., Stratakis C., Lindpaintner K., Vickery B., Foernzler D., Van Hul W. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum. Mol. Genet. 2001, 10:537-543.
15. Balemans W., Patel N., Ebeling M., Van Hul E., Wuyts W., Lacza C., Dioszegi M., Dikkers F.G., Hildering P., Willems P.J., Verheij J.B., Lindpaintner K., Vickery B., Foernzler D., Van Hul W. Identification of a 52kb deletion downstream of the SOST gene in patients with van Buchem disease. J. Med. Genet. 2002, 39:91-97.
16. Padhi D., Jang G., Stouch B., Fang L., Posvar E. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J. Bone Miner. Res. 2011, 26:19-26.
17. Mirza F.S., Padhi I.D., Raisz L.G., Lorenzo J.A. Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women. J. Clin. Endocrinol. Metab. 2010, 95:1991-1997.
18. Drake M.T., Srinivasan B., Modder U.I., Peterson J.M., McCready L.K., Riggs B.L., Dwyer D., Stolina M., Kostenuik P., Khosla S. Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J. Clin. Endocrinol. Metab. 2010, 95:5056-5062.
19. Modder U.I., Clowes J.A., Hoey K., Peterson J.M., McCready L., Oursler M.J., Riggs B.L., Khosla S. Regulation of circulating sclerostin levels by sex steroids in women and in men. J. Bone Miner. Res. 2011, 26:27-34.
20. Chung Y.E., Lee S.H., Lee S.Y., Kim S.Y., Kim H.H., Mirza F.S., Lee S.K., Lorenzo J.A., Kim G.S., Koh J.M. Long-term treatment with raloxifene, but not bisphosphonates, reduces circulating sclerostin levels in postmenopausal women. Osteoporos. Int. 2011.
21. Vincent C., Findlay D.M., Welldon K.J., Wijenayaka A.R., Zheng T.S., Haynes D.R., Fazzalari N.L., Evdokiou A., Atkins G.J. Pro-inflammatory cytokines TNF-related weak inducer of apoptosis (TWEAK) and TNFalpha induce the mitogen-activated protein kinase (MAPK)-dependent expression of sclerostin in human osteoblasts. J. Bone. Miner. Res. 2009, 24:1434-1449.
22. Leupin O., Kramer I., Collette N.M., Loots G.G., Natt F., Kneissel M., Keller H. Control of the SOST bone enhancer by PTH using MEF2 transcription factors. J. Bone Miner. Res. 2007, 22:1957-1967.
23. Mecklenburg L., Tychsen B., Paus R. Learning from nudity: lessons from the nude phenotype. Exp. Dermatol. 2005, 14:797-810.
24. Roggia C., Gao Y., Cenci S., Weitzmann M.N., Toraldo G., Isaia G., Pacifici R. Up-regulation of TNF-producing T cells in the bone marrow: a key mechanism by which estrogen deficiency induces bone loss in vivo. Proc. Natl. Acad. Sci. USA 2001, 98:13960-13965.
25. Kimble R.B., Bain S., Pacifici R. The functional block of TNF but not of IL-6 prevents bone loss in ovariectomized mice. J. Bone Miner. Res. 1997, 12:935-941.
26. Cenci S., Weitzmann M.N., Roggia C., Namba N., Novack D., Woodring J., Pacifici R. Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha. J. Clin. Invest. 2000, 106:1229-1237.
27. Ryan M.R., Shepherd R., Leavey J.K., Gao Y., Grassi F., Schnell F.J., Qian W.P., Kersh G.J., Weitzmann M.N., Pacifici R. An IL-7-dependent rebound in thymic T cell output contributes to the bone loss induced by estrogen deficiency. Proc. Natl. Acad. Sci. USA 2005, 102:16735-16740.
28. Keller H., Kneissel M. SOST is a target gene for PTH in bone. Bone 2005, 37:148-158.
29. Papanicolaou S.E., Phipps R.J., Fyhrie D.P., Genetos D.C. Modulation of sclerostin expression by mechanical loading and bone morphogenetic proteins in osteogenic cells. Biorheology 2009, 46:389-399.
30. Pederson L., Ruan M., Westendorf J.J., Khosla S., Oursler M.J. Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate. Proc. Natl. Acad. Sci. USA 2008, 105:20764-20769.